Search details
1.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30755741
2.
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Mol Cancer
; 23(1): 64, 2024 03 26.
Article
in English
| MEDLINE | ID: mdl-38532456
3.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Cancer
; 130(3): 400-409, 2024 02 01.
Article
in English
| MEDLINE | ID: mdl-37864520
4.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Article
in English
| MEDLINE | ID: mdl-38297981
5.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Article
in English
| MEDLINE | ID: mdl-29420467
6.
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Oncologist
; 28(12): 1100-e1292, 2023 Dec 11.
Article
in English
| MEDLINE | ID: mdl-37311055
7.
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
; 150(6): 993-1006, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34724226
8.
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.
Cancer
; 128(18): 3383-3391, 2022 09 15.
Article
in English
| MEDLINE | ID: mdl-35792683
9.
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
Invest New Drugs
; 40(1): 99-105, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34468905
10.
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Invest New Drugs
; 40(2): 290-299, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34562230
11.
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Invest New Drugs
; 40(1): 124-133, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34559346
12.
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
Gynecol Oncol
; 166(2): 211-218, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35361487
13.
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.
Br J Clin Pharmacol
; 88(7): 3392-3403, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35236002
14.
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Cancer
; 127(3): 391-402, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-33119140
15.
Overview of Ocular Side Effects of Selinexor.
Oncologist
; 26(7): 619-623, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33728727
16.
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Invest New Drugs
; 39(5): 1324-1334, 2021 10.
Article
in English
| MEDLINE | ID: mdl-33774767
17.
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
Invest New Drugs
; 39(4): 1047-1056, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33594602
18.
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Invest New Drugs
; 39(5): 1357-1365, 2021 10.
Article
in English
| MEDLINE | ID: mdl-33909232
19.
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Lancet Oncol
; 21(10): 1353-1365, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32919526
20.
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
Int J Cancer
; 147(8): 2190-2198, 2020 10 15.
Article
in English
| MEDLINE | ID: mdl-32359091